# National Institute of Unani Medicine, Bengaluru: Phase 2 study in MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) (128 participants)

**Score:** 80/100

| Field | Value |
|---|---|
| Sponsor | National Institute of Unani Medicine, Bengaluru |
| Sponsor type | Academic and hospital |
| Study | Qurse Revand for MASLD: A Randomized Controlled Safety and Efficacy Trial |
| NCT ID | NCT07902219 |
| Phase | Phase 2 |
| Status | not yet recruiting |
| Conditions | MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease) |
| Intervention types | drug |
| Target enrollment | 128 |
| Site countries | India |
| Posted | 2026-10-28 |
| Planned start | 2027-05-01 |
| Event | Newly registered study |
| Event date | 2026-10-28 |

## Why this score
- Posted in the last two weeks.
- Phase 2: multi-site, larger budget.
- 128 participants planned.
- Not yet recruiting: vendors still being chosen.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT07902219). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.